Ulixacaltamide

Small molecule

Filedunder review

Evidence outlook · regulatory review

Essential Tremor: application under FDA review, decision date 2027-01-29

FDA accepted the NDA for ulixacaltamide HCl in essential tremor (2026-04-14). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.

NCT06087276: Essential3 was a randomized, triple-masked Phase 3 programme in essential tremor. Both pivotal studies met their primary endpoints according to the company's topline release. The sources read give no power calculation, so the grade is moderate.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Essential Tremor
Phase 2 (2)
Essential Tremor
NCT05021991 · Praxis Precision Medicines
2021-10-14 – 2024-02-29 · Essential Tremor
What this study did
NCT05021978 · Praxis Precision Medicines
2020-03-03 – 2022-03-24 · Essential Tremor
What this study did

Competitive landscape

Other T-type calcium channel drugs

Ethosuximide. Compare all 2 T-type calcium channel drugs

1 other tracked programme targets this mechanism, 1 of them ahead of this one.

This drug's own stage for Essential Tremor: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ulixacaltamide: this drugPhase 3Small moleculeT-type calcium channelPartial signal
NCT06087276: Both pivotal Essential3 studies met their primary endpoints: Study 1, mADL11 improvement at week 8; Study 2, maintenance of effect in randomized withdrawal (Praxis, 2025-10-16).
Ethosuximide
Approved(overall)
Small moleculeT-type calcium channel
Reliable signal(overall)
No reviewed efficacy summary in this indication
GemibotulinumtoxinA
—(overall)
Botulinum ToxinSNAP-25not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

29 January 2027FDA action datePDUFA target action date for ulixacaltamide HCl in essential tremor
US, FDA · FDA · Source ↗

Recent

14 April 2026Filing acceptedFDA accepted the NDA for ulixacaltamide HCl in essential tremor
US, FDA · Praxis Precision Medicines · Source ↗
16 October 2025Topline resultEssential3 phase 3 topline
Praxis Precision Medicines · Source ↗